Government Action/Industry Reaction: HHS Sees Success In Approach To Drug Pricing Solutions
US HHS officials Azar and O’Brien tell a National Academy of Medicine forum that an important element of the Trump Administration’s approach to lowering drug prices is eliciting voluntary change from market players.
You may also be interested in...
From kinds of ads targeted to agency that's issuing the reg, policy seems designed to withstand a court challenge.
Member companies’ direct-to-consumer TV ads will direct patients to information about drug costs – including list price, estimated out-of-pocket costs for the drug, and availability of financial assistance – under a voluntary program that takes effect in April 2019; initiative falls short of mandatory list price disclosures proposed by Trump Administration.
Remicade, Procrit, Aranesp and biosimilars will be subject to step therapy in limited number of Medicare Advantage plans in 2019.